Projects

Chosen filters:
Chosen filters:

1 - 10 of 69 results

Sorteren op
Search term:

Identification of potent single-domain antibodies against the malaria sporozoite through a synthetic single-domain antibody library containing unconventional diversification strategies. University of Antwerp

Yann Sterckx
Laboratory for Microbiology, Parasitology and Hygiene (LMPH), Medical Biochemistry
Malaria, caused by Plasmodium parasites, is one of the 'Big Three' infectious diseases, together with HIV and TB. Each year more than 200 million cases of the disease are documented, including more than half a million deaths (>76% of the deceased are children under the age of five). Problems are worsened due to low-efficacy vaccines, drug-resistant parasites and the (re-)emergence of the disease around the globe. This clearly indicates that ...

SRP-Groeifinanciering: Single-domain antibody fragment (SdAb)-based TArgeted Radionuclide Therapy: STaRT programme Vrije Universiteit Brussel

Clinical sciences, Supporting clinical sciences
The Strategic Research Programme - Growth - SdAb-based Targeted Radionuclide Therapy (STaRT) brings together a unique group of experts that aims to conduct a patient-focused STaRT programme with the potential of clinical translation in the next 5 years. The consortium intents to preclinically validate and translate into the clinic a single-domain antibody fragment (sdAb)-based platform as a tool for targeted radionuclide therapy (TRNT) of ...

Pandemic preparedness against protozoan parasites through the establishment of a hybrid camelid single-domain antibody platform. University of Antwerp

Yann Sterckx
Laboratory for Microbiology, Parasitology and Hygiene (LMPH), Veterinary physiology and biochemistry, Institute of Tropical Medicine Antwerp (ITG), Vrije Universiteit Brussel, Medical Biochemistry
Infectious disease research (including diagnostic, preventative and therapeutic development) has been a longstanding spearhead initiative of the University of Antwerp. This is driven by a vibrant research community, which is embedded in a larger "infectious disease ecosystem" in Flanders. A significant portion of these efforts is specifically devoted towards tackling protozoan parasites, a group of unicellular eukaryotes that affect the ...

Evaluation of an in vivo pre-targeting approach for targeted radionuclide therapy of cancer using clickable anti-B7-H3 single domain antibodies. Vrije Universiteit Brussel

Matthias D'Huyvetter, Nick Devoogdt
Medical Imaging, Supporting clinical sciences
Targeted radionuclide therapy (TRNT) is an attractive therapeutic
approach as it can specifically deliver lethal radiation doses both to
the primary tumour site as well as disseminated disease, while
sparing non-target organs. TRNT using full-sized antibodies as
vectors remains challenging in solid tumours due to their long
circulation time. Single-domain antibody fragments (sdAbs) are
vectors with ...

Designed, broadly protective antibodies directed against influenza B. Ghent University

Department of Biochemistry and microbiology

Influenza B viruses (IBVs) cause a quarter of all human influenza cases and in some seasons even dominate influenza A. In the past 3 decades, the world has witnessed a worrying antigenic diversification of IBVs, first with the emergence in the 1980s of the steadily separating Victoria and Yamagata antigenic lineages. More recently, the Yamagata lineage in its turn has started to bifurcate antigenically. In general, currently licensed ...

Perturbation of apolipoprotein E4 (apoE4) activity in AD pathology using single domain antibodies and targeting them to the brain Ghent University

Jan Gettemans
Department of Biomolecular Medicine, Department of Pharmaceutics

The APOE-ε4 allele is the most prominent genetic risk factor for late onset AD. We will use ApoE4 nanobodies to stabilize the non-pathological conformation of ApoE4, and use photoporation as a means of introducing nanobodies in mammalian cells. In addition, we plan to target nanobodies to the brain in collaboration with prof. Breakefield (Dept. Neurology, Harvard Medical School, Boston).